Vancouver, Canada, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated...Read more
November 24, 2025 - Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP). This marks the first European site...Read more
New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 PLYMOUTH MEETING, Pa. / Nov 24, 2025 / Business Wire / Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced positive...Read more
CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has...Read more
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a...Read more
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode each year CHATHAM, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| IDEXX Laboratories | 28.24 3.89 | $754.15 |
| Inspire Medical Systems | 25.76 28.66 | $115.63 |
| Tenet Healthcare | 19.65 10.24 | $211.61 |
| Medpace | 16.18 2.73 | $608.00 |
| GRAIL | 15.92 17.02 | $109.47 |
| Madrigal Pharmaceuticals | 14.94 2.73 | $562.90 |
| HCA Healthcare | 14.69 2.99 | $505.69 |
| Belite Bio | 13.69 11.36 | $134.25 |
| GeneDx | 12.96 8.84 | $159.52 |
| Meihua Medical Technologies | 10.92 7,509.35 | $11.06 |
| Mettler-Toledo | 10.69 0.74 | $1,463.04 |
| Elevance Health | 9.88 3.07 | $331.61 |
| TransMedics | 8.86 6.77 | $139.79 |
| Movano Health | 8.44 271.38 | $11.55 |
| Insulet | 8.17 2.47 | $339.34 |
| Penumbra | 7.89 2.74 | $296.36 |
| Natera | 7.28 3.16 | $237.91 |
| Monopar Therapeutics | 7.23 7.90 | $98.79 |
| Company | Volume | Last Trade |
|---|---|---|
| Enlivex Therapeutics | 709,696,871 | $1.24 |
| Pasithea Therapeutics | 71,503,363 | $0.36 |
| Novo Nordisk | 59,241,543 | $45.05 |
| Oscar Health | 45,215,648 | $16.20 |
| Amicus Therapeutics | 29,233,788 | $9.67 |
| Pfizer | 26,222,666 | $25.43 |
| Incannex Healthcare | 18,761,088 | $0.34 |
| Zynex | 17,953,530 | $0.75 |
| Iovance Biotherapeutics | 15,410,284 | $2.49 |
| Sangamo Therapeutics | 15,117,970 | $0.42 |
| PacBio | 15,019,540 | $2.46 |
| Moleculin Biotech | 14,434,875 | $0.36 |
| Merck | 14,284,573 | $101.73 |
| Applied Therapeutics | 13,537,432 | $0.26 |
| Plus Therapeutics | 12,891,816 | $0.57 |
| Bristol-Myers Squibb | 12,011,485 | $48.44 |
| Recursion | 11,839,864 | $4.23 |
| FibroBiologics | 11,748,677 | $0.26 |
| Centene | 11,681,759 | $38.57 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
